The therapy is approved by the U.S. Food and Drug Administration for relapsed or treatment - resistant Hodgkin lymphoma, and it is commonly prescribed to patients whose disease has progressed
after autologous stem cell transplant, a procedure that replenishes the
bone marrow with the patient's own healthy stem cells
after therapy.